This study investigates the use of irinotecan liposome injection combined with oxaliplatin and tegafur as a treatment after surgery for pancreatic cancer.
The study evaluates the safety and effectiveness of this treatment combination for patients who have had surgery for pancreatic cancer.
- Who can participate: Adults with resected ductal pancreatic adenocarcinoma and a life expectancy of at least 6 months may participate. Participants should have an ECOG performance status of 0 or 1.
- Study details: Participants will receive a combination of irinotecan liposome, oxaliplatin, and tegafur after surgery. The study will monitor the safety and effectiveness of this treatment.